Verastem to Present at the 16th Annual Needham Healthcare Conference
April 03 2017 - 7:00AM
Business Wire
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and
developing drugs to treat cancer, today announced that the company
will present at the 16th Annual Needham Healthcare Conference on
Tuesday, April 4th at 3:00 p.m. ET at The Westin Grand Central in
New York City.
A live audio webcast of the presentation will be available on
the company’s website at www.verastem.com. An archived
presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company
focused on discovering and developing drugs to improve outcomes for
patients with cancer. Verastem is currently developing
duvelisib, a dual inhibitor of phosphoinositide-3-kinase
(PI3K)-delta and PI3K-gamma, which has successfully met its primary
endpoint in a Phase 2 study in iNHL and is currently being
evaluated in a Phase 3 clinical trial in patients with chronic
lymphocytic leukemia (CLL). In addition, Verastem is
developing the focal adhesion kinase (FAK) inhibitor defactinib,
which is currently being evaluated in three separate clinical
collaborations in combination with immunotherapeutic agents for the
treatment of several different cancer types, including pancreatic
cancer, ovarian cancer and non-small cell lung cancer, and
mesothelioma. Verastem’s product candidates seek to treat cancer by
modulating the local tumor microenvironment, enhancing anti-tumor
immunity and reducing cancer stem cells. For more information,
please visit www.verastem.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170403005344/en/
Verastem, Inc.Brian Sullivan, 781-292-4214Director,
Corporate Developmentbsullivan@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Apr 2023 to Apr 2024